Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Healthy based on medical examination/history at the inclusion~* Age between 18 and 55 years~* Signed informed consent~* Prepared to grant authorized persons access to the medical records~* The volunteer is likely to comply with instructions~Exclusion Criteria:~* Known exposure to TB before (or expected during) the trial~* Prior BCG vaccination~* Granulomatous disease (by chest X-ray, autoimmune screen)~* Vaccinated with live vaccine 3 months before first vaccination~* Administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination~* HBV, HCV or HIV sero-positive (HBsAg, HBsAb, HBc total and IgM ab and HCV, HIV-1 and HIV2 ab)~* Participation in other clinical trials~* Positive Mantoux or QuantiFERON-TB Gold~* Known hypersensitivity to any of the vaccine components~* Laboratory parameters outside of normal ranges considered clinically relevant

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Antigen group + high adjuvans (Type: EXPERIMENTAL): The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
- Antigen group (Type: EXPERIMENTAL): The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
- Antigen + low adjuvans group (Type: EXPERIMENTAL): The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).